Differentiating struma ovarii from FIGO stage I malignant ovarian tumors in O-RADS MRI 5 lesions: a targeted cohort study.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Performance of MRI protocols for diagnosis of benign and malignant ovarian tumors: a systematic review and meta-analysis.Abdominal radiology (New York) · 2026
   Pooled it
2. Differentiating Borderline from Malignant Ovarian-Adnexal Tumours: A Multimodal Predictive Approach Joining Clinical, Analytic, and MRI Parameters.Cancers · 2026
   Article
3. Computed tomography and magnetic resonance imaging features of struma ovarii: A retrospective case series.Journal of clinical imaging science · 2026
   Article
4. Individualized survival prediction and risk stratification using machine learning for patients with malignant struma ovarii: a population-based study with external validation.Gland surgery · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

Abstract

PubMed holds no abstract for this paper.